NEW YORK (GenomeWeb) – Biocept today announced that it has signed two new agreements with preferred provider organization networks — Fortified Provider Network and Three Rivers Provider Network.

Under the deals, the approximately 26 million members of these two PPOs will now have covered access to Biocept's Target Selector non-invasive liquid biopsy assays, which include tests for melanoma, breast, lung, and gastric cancer biomarkers.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.